Coxibs: Highly selective cyclooxygenase-2 inhibitors. Part 1. Clinical efficacy;Koksiby - Wysoce selektywne inhibitory cyklooksygenazy-2. Czȩść I. Aktywność kliniczna

Polski Merkuriusz Lekarski

Volumn 14, Issue 82, 2003, Pages 348-351

  Burdan, Franciszek ^a   Korobowicz, Agnieszka ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Acute pain; Alzheimer disease; COX 1; COX 2; Cyclooxygenase; Fever; Neoplasm; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; ISOPROTEIN; MELOXICAM; NAPROXEN; NIMESULIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

ALZHEIMER DISEASE; CHRONOTHERAPY; DRUG EFFICACY; DRUG SELECTIVITY; FEVER; GENE EXPRESSION; HUMAN; INFLAMMATION; NEOPLASM; OSTEOARTHRITIS; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ALZHEIMER DISEASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEVER; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 0037698708     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Bensen W.G. i wsp.: Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomizrd controlled trial. Mayo Clin. Proc., 1999, 74, 1095-1105.
2. Cannon G.W. i wsp.: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Results of a one-year, randomised, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum., 2000, 43, 978-987.
3. Crofford L.J. i wsp.: Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effect of interleukin-1 beta, phorbal ester, and corticosteroid. J. Clin. Invest., 1994, 93, 1095-1101.
4. Dannhardt G., Kiefer W.: Cyclooxygenase inhibitors - current status and future prospects. Eur. J. Med. Chem., 2001, 36, 109-126.
5. Day R. i wsp.: A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Iburprofen Comparator Study Group. Arch. Intern. Med., 2000, 160, 1781-1787.
6. Dempke W. i wsp.: Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol., 2001, 127, 411-417.
7. Dougados M. i wsp.: Efficacy of celecoxib, a cyclooxygenase 2 specific inhibitor, in treatment of ankylosing spondylitis. Arthritis Rheum., 2001, 44, 180-185.
8. Ehrich E. i wsp.: MK-0966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum., 1997, 40 (suppl. 1), S85 (abstract).
9. Ehrich E.W. i wsp.: Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J. Rheumatol., 1999, 26, 2438-2446.
10. Ehrich E. i wsp.: Characterisation of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin. Pharmacol. Ther., 1999, 65, 336-347.
11. Emery P. i wsp.: Celecoxib versus diclaofenac in long-term managment of rheumatoid arthritis: randomised double-blind comparison. Lancet, 1999; 354, 2106-2111.
12. Garavito R.M. i wsp: Strategies for crystallizing membrane proteins. J. Bioenerg. Biomembr., 1996, 28, 13-27.
13. Hubbard R.C. i wsp.: S.C.-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J. Invest. Med., 1996, 44, 293 (abstract).
14. Kawamori T. i wsp.: Chemopreventaive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 1998, 58, 409-412.
15. Kosaka T. i wsp.: Characterisation of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem., 1994, 221, 889-897.
16. Kurumbail R.G. i wsp.: Structural basis for selective inhibition of cylooxygense-2b anti-inflammatory agents. Nature, 1996, 384, 644-648; 1997, 385, 555.
17. Kurumbail R.G. i wsp.: Structural basis for selective inhibition of cylooxygense-2b anti-inflammatory agents. Nature, 1996, 384, 644-648; 1997, 385, 555.
18. Malmstrom I.K. i wsp.: Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomised, placebo- and active-comparator trial. Clin. Ther., 1999, 21, 1653-1662.
19. Maridini I.A., FitzGerald G.: Selective Inhibitors of cyclooxygenase-2. A rowing class of anti-inflammatory drugs. Molecular Interv., 2001, 1, 30-38.
20. McGeer P.L.: Cyclo-oxygenase-2 inhibitors. Rationale and therapeutic potential for Alzheimer's disease. Drug Aging, 2000, 17, 1-11.
21. Morrison B.W. i wsp.: Analgesic efficacy of the cyclooxygenase-2 specific inhibitor rofecoxib in post-dental surgery pain: a randomised, controlled trial. Clin. Ther., 1999, 21, 943-953.
22. Morrison B.W. i wsp.: Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomised controlled trial. Obstet. Gynecol., 1999, 94, 504-508.
23. Reddy B.S. i wsp.: Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventative properties in colon carcinogenesis. Cancer Res., 1996, 56, 4566-4569.
24. Roth S.H.: NSAID gastropathy - a new understanding. Arch Intern. Med., 1996, 156, 1623-1628.
25. Sainali S.M. i wsp.: Results of double-blind, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's diseases. Abstract from 6th International Stockholm-Springfield Symposium of Advences in Alzheimer's Therapy, 2000.
26. Schnitzer T.J. i wsp.: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin. Ther., 1999, 21, 1688-1702.
27. Schonbeck U. i wsp.: Augumented expression of cyclooxygense-2 in human atherosclerotic lesion. Am. J. Pathol., 1999, 155, 1281-191.
28. Schwartz J.I. i wsp.: Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin. Pharmacol. Ther., 1999, 65, 653-660.
29. Sheng H. i wsp.: Transforming growth factor-beta1 enhances Ha-res-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem., 2000, 275, 6628-6635.
30. Simmons D.L. i wsp.: Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroidal antiinflammatory drugs. Proc. Nat. Acad. Sci. USA, 1999, 96, 3275-3280.
31. Simon L.S. i wsp.: Preliminary Study of the safety and efficacy of S.C.-58635, a novel cyclooxygenase 2 inhibitor. Arthritis Rheum., 1998, 41, 1591-1602.
32. Simon L.S. i wsp.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomised controlled trial. JAMA, 1999, 282, 1921-1928.
33. Tazawa R. i wsp.: Characterisation of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem. Biophys. Res. Commun., 1994, 203, 190-199.
34. Vane J.R., Warner T.D.: Nomenclature for COX-2 inhibitors. Lancet, 2000, 356, 1373-1374.
35. Wolfe F. i wsp.: Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J. Rheumatol., 2001, 28, 1423-1430.
36. Zimmermann-Górska I.: Postȩpy w medycynie w 2000 roku - opinie polskich specjalistów: Reumatologia. Med. Praktyczna, 2002, 12, 143-152.